National Engineering Research Center of Cell Products, Tianjin AmCellGene Engineering Co., Ltd, Tianjin, China.
Curr Stem Cell Res Ther. 2021;16(3):277-285. doi: 10.2174/1574888X15999200729161539.
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since Dec 2019, known as COVID-19 or 19-nCoV, has led to a major concern of the potential for not only an epidemic but a pandemic in China and now it seems to be a public health problem all over the world. The general mortality rate of the COVID-19 was about 3%. However, the mortality risk seems to be a significant increase in elderly and cases with chronic disease, who are more likely to develop into acute respiratory distress syndrome (ARDS). There still lacks effective methods for ARDS of COVID-19 patients and the prognosis was poor. Mesenchymal Stem Cells (MSCs) based treatment has the advantage of targeting numerous pathophysiological components of ARDS by secreting a series of cell factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. Recently, pilot clinical studies indicated MSCs based therapy was promise in treatment of ARDS caused by SARS-CoV-2. However, little is known about MSCs therapy for ARDS caused by COVID-19.
自 2019 年 12 月以来，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的爆发，被称为 COVID-19 或 19-nCoV，不仅在中国引起了人们对流行的潜在担忧，而且现在似乎也成为了全世界的公共卫生问题。COVID-19 的总体死亡率约为 3%。然而，死亡率风险似乎在老年患者和患有慢性病的患者中显著增加，这些患者更容易发展为急性呼吸窘迫综合征（ARDS）。目前仍然缺乏 COVID-19 患者 ARDS 的有效治疗方法，预后较差。间充质干细胞（MSCs）治疗具有通过分泌一系列细胞因子靶向 ARDS 众多病理生理成分的优势，发挥抗炎、抗氧化、免疫调节、抗凋亡和促血管生成作用，从而在各种临床前模型中导致 ARDS 后的显著结构和功能恢复。最近，初步临床研究表明，基于 MSCs 的治疗方法在治疗由 SARS-CoV-2 引起的 ARDS 方面有希望。然而，对于 COVID-19 引起的 ARDS 的 MSCs 治疗，我们知之甚少。
